Climb Bio, Inc. Common Stock (CLYM) Stock Price
CLYMStock
$14.57+533.48%52W
Market Cap$836.85M
P/E—
PEG Ratio—
Div yield—
Beta-0.02
CLYM Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)117.16%
Price vs S&P 500 (4W)21.83%
VGM Score77.75
CLYM Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.21 | -$0.18 | +15.29%(+$0.03) | |
| Q1 2026 | -$0.30 | -$0.20 | +33.58%(+$0.10) | |
| Q4 2025 | -$0.21 | -$0.26 | -25.80%(-$0.05) | |
| Q3 2025 | -$0.14 | -$0.19 | -31.03%(-$0.05) | |
| Q2 2025 | -$0.18 | -$0.13 | +29.73%(+$0.05) |
CLYM Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.42
4.40
4.43
4.45
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CLYMClimb Bio, Inc. Common Stock | — | — | B | $14.57 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Climb Bio, Inc. Common Stock
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases. Its lead candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete B cells for the treatment of B-cell-mediated diseases.